MetaCap

Can-Fite Biopharma (CANF) vs Lantern Pharma (LTRN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Can-Fite Biopharma (CANF) has outperformed Lantern Pharma (LTRN) over the past year, losing 75.3% versus a loss of 91.9%. Over five years, LTRN leads with a -97.3% price change compared with -99.4% for CANF. Can-Fite Biopharma is the larger company by market cap ($4.4 million vs $3.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CANF-75.26%LTRN-91.89%
+45%-27%-98%
Nov 21, 20251 yearNov 20, 2026
CANF-99.41%LTRN-97.27%
+24%-40%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CANF versus LTRN key metrics
MetricCANFLTRN
Share price$1.44$0.245
Market cap$4.35M$3.89M
1-day change-2.34%-13.73%
YTD return-64.13%-91.91%
1-year return-75.26%-91.89%
5-year return-99.42%-97.27%
EPS (TTM)$-13.23$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$405.00K—
Revenue growth (YoY)-39.91%—
Net income (latest FY)$-9.83M$-17.12M
Operating margin-2456.79%—
Net margin-2426.67%—
52-week high$10.40$4.34
52-week low$1.42$0.2286
Distance from 52-week high-86.20%-94.35%
Analyst consensusstrong_buynone
Avg. price target upside+457.49%+7042.86%
Average volume375.00K249.66K
Shares outstanding3.03M15.89M
Employees516
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CANF has outperformed LTRN by 16.6 percentage points over the past year.

About Can-Fite Biopharma

CANF stock →

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Lantern Pharma

LTRN stock →

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

CANF vs LTRN FAQ

Which is bigger, Can-Fite Biopharma or Lantern Pharma?

Can-Fite Biopharma (CANF) is larger, with a market capitalization of $4.35M compared with $3.89M for Lantern Pharma (LTRN).

Which stock has performed better over the past year, CANF or LTRN?

CANF returned -75.26% over the past 12 months, compared with -91.89% for LTRN (price return, excluding dividends). Past performance does not predict future results.

Are Can-Fite Biopharma and Lantern Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons